A vs BVS: fair value comparison
Agilent Technologies, Inc. and Bioventus Inc. · Updated 2026-10-19
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, A currently sits closer to the top of our ranking by discount to fair value.
| A | BVS | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $170.54 | $13.30 |
| 12-month range | $110.24–$175.55 | $6.53–$15.26 |
| Rank by discount to fair value | #62 of 108 Healthcare | #67 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: A fair value analysis · BVS fair value analysis